{"id":"vaccinated-with-bopv","safety":{"commonSideEffects":[{"rate":null,"effect":"Vaccine-derived poliovirus (VDPV) shedding"},{"rate":null,"effect":"Mild gastrointestinal symptoms"},{"rate":null,"effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL373625","moleculeType":"Small molecule"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"bOPV is a live attenuated vaccine containing weakened strains of poliovirus types 1 and 3. When administered orally, it replicates in the intestinal tract and triggers both mucosal and systemic immune responses, generating neutralizing antibodies and cellular immunity. This protects vaccinated individuals from infection and disease caused by wild-type poliovirus.","oneSentence":"bOPV (bivalent oral polio vaccine) stimulates the immune system to produce antibodies against poliovirus types 1 and 3, providing protection against poliomyelitis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:39:17.700Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of poliomyelitis caused by poliovirus types 1 and 3"}]},"trialDetails":[{"nctId":"NCT03554798","phase":"PHASE2","title":"A Study to Evaluate the Safety and Immunogenicity of Novel Oral Polio Vaccine","status":"COMPLETED","sponsor":"Fidec Corporation","startDate":"2018-12-04","conditions":"Poliomyelitis","enrollment":1025},{"nctId":"NCT03581734","phase":"PHASE3","title":"Immunogenicity of Co-administered Oral Polio Vaccine and Oral Cholera Vaccine","status":"UNKNOWN","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2018-07-01","conditions":"Vaccine Reaction","enrollment":579},{"nctId":"NCT04576910","phase":"PHASE4","title":"Immunogenicity and Safety of the Booster Dose of Polio Vaccine With Different Primary Sequential Schedules in China","status":"COMPLETED","sponsor":"Zhejiang Provincial Center for Disease Control and Prevention","startDate":"2020-11-05","conditions":"Polio, Vaccine Reaction","enrollment":387},{"nctId":"NCT04054492","phase":"PHASE4","title":"To Evaluate the Immunogenicity and Safety of Sequential Immunization Schedules of Sabin IPV and bOPV","status":"COMPLETED","sponsor":"China National Biotec Group Company Limited","startDate":"2018-03-01","conditions":"Vaccination, Reaction - Vaccine","enrollment":604},{"nctId":"NCT01831050","phase":"PHASE4","title":"Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine","status":"COMPLETED","sponsor":"Fidec Corporation","startDate":"2013-05","conditions":"Poliomyelitis","enrollment":1420}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":162,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"vaccinated with bOPV","genericName":"vaccinated with bOPV","companyName":"Zhejiang Provincial Center for Disease Control and Prevention","companyId":"zhejiang-provincial-center-for-disease-control-and-prevention","modality":"Biologic","firstApprovalDate":"","aiSummary":"bOPV (bivalent oral polio vaccine) stimulates the immune system to produce antibodies against poliovirus types 1 and 3, providing protection against poliomyelitis. Used for Prevention of poliomyelitis caused by poliovirus types 1 and 3.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}